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Abstract
Background
Inflammatory bowel disease (IBD) is a chronic disease placing a large health and economic
burden on health systems worldwide. The treatment landscape is complex with multiple
strategies to induce and maintain remission while avoiding long-term complications. The
extent to which rising treatment costs, due to expensive biologic agents, are offset by
improved outcomes and fewer hospitalisations and surgeries needs to be evaluated. This
systematic review aimed to assess the cost-effectiveness of treatment strategies for IBD.
Materials and methods
A systematic literature search was performed in March 2017 to identify economic evaluations
of pharmacological and surgical interventions, for adults diagnosed with Crohn’s disease
(CD) or ulcerative colitis (UC). Costs and incremental cost-effectiveness ratios (ICERs) were
adjusted to reflect 2015 purchasing power parity (PPP). Risk of bias assessments and a nar-
rative synthesis of individual study findings are presented.
Results
Forty-nine articles were included; 24 on CD and 25 on UC. Infliximab and adalimumab
induction and maintenance treatments were cost-effective compared to standard care in
patients with moderate or severe CD; however, in patients with conventional-drug refractory
CD, fistulising CD and for maintenance of surgically-induced remission ICERs were above
acceptable cost-effectiveness thresholds. In mild UC, induction of remission using high
dose mesalazine was dominant compared to standard dose. In UC refractory to conven-
tional treatments, infliximab and adalimumab induction and maintenance treatment were
not cost-effective compared to standard care; however, ICERs for treatment with vedolizu-
mab and surgery were favourable.
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Conclusions
We found that, in general, while biologic agents helped improve outcomes, they incurred high
costs and therefore were not cost-effective, particularly for use as maintenance therapy. The
cost-effectiveness of biologic agents may improve as market prices fall and with the introduc-
tion of biosimilars. Future research should identify optimal treatment strategies reflecting rou-
tine clinical practice, incorporate indirect costs and evaluate lifetime costs and benefits.
Introduction
Inflammatory bowel disease (IBD) refers mainly to Crohn’s disease (CD) and ulcerative colitis
(UC), which are chronic, autoimmune conditions causing inflammation in the gastrointestinal
tract and extra-intestinal complications. IBD follows a course of exacerbation and remission of
inflammation with symptoms characterised by chronic abdominal pain, diarrhoea and weight
loss [1].
The clinical management of IBD aims to induce and maintain remission in patients with
active disease [2]. Treatment strategies are complex, consisting of pharmacological treatment
and surgery depending on disease location, severity and patients’ treatment history [3]. The
traditional step-up approach consists of first-line therapy with “conventional” or standard
of care treatments such as aminosalicylates, corticosteroids, and immunomodulators (e.g.
azathiopurine, 6-mercaptopurine) [4]. More recently, biologic agents are being used to induce
remission in patients with moderate to severe disease and disease which responds poorly or is
refractory to conventional medicines [5, 6]. Anti-tumour necrosis factor (TNF) agents, inflixi-
mab, adalimumab, and golimumab are approved for use in CD and UC by the European Med-
icine’s Agency (EMA) and the USA Food and Drug Administration (FDA); certolizumab
pegol is approved only for CD in Switzerland, the USA and Russia [7]. In addition, two anti-
integrin molecules are available: vedolizumab, approved in the USA and Europe for CD and
UC, and natalizumab, approved in the USA for CD only. These agents provide promising
alternatives to conventional medications as they are associated with reduced dependence on
corticosteroids as well as longer duration of remission and improved overall quality of life [8].
IBD is among the top five most expensive gastrointestinal disorders to treat; it incurs wider
social costs and reduces patients’ quality of life [9]. Within Europe, estimates from 2013 sug-
gest that 2.5–3 million people are affected with IBD contributing an overall direct health care
cost of 4.6–5.6 billion Euros per year [10]. These figures are higher in the USA, which has an
estimated prevalence of 214 per 100,000 individuals for CD and UC each [6, 11]. The increas-
ing prevalence, high morbidity and costs of IBD represent an important challenge, requiring
resources and infrastructure for efficient long-term chronic disease management [11, 12].
The economic burden of IBD is changing whereby costs are increasingly driven by biologic
agents and less by hospitalisations and surgery [13]. Despite the high costs of biologic agents,
increasing use of these agents is seen due to their efficacy [14]. Given the uncertainties around
the optimal use of biologic agents in IBD, increased scrutiny on the cost-effectiveness of differ-
ent treatment strategies is required to aid cost-containment discussions while still ensuring
patients’ receive the best available treatments. Economic evaluations aim to compare alterna-
tive strategies by relating the improvement in health outcomes to the overall treatment costs
across health states and over time in order to inform decision-making on the optimal use of
available resources [15]. We conducted a systematic literature review of the cost-effectiveness
of pharmacological or surgical interventions in adults diagnosed with CD or UC across differ-
ent health systems and a spectrum of clinical presentations. The objective of this review was to
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provide an understanding of the cost-effective treatment strategies, particularly the biologic
agents, and identify gaps in the literature and requirements for future economic models in
IBD.
Materials and methods
Literature search
An extensive literature search was performed on 16 November 2016 and updated on 21 March
2017 in key databases: Ovid Medline (1946 to present), Embase (1974 to Nov 14, 2011), Data-
base of Abstracts of Reviews of Effects (DARE, 1994 to March 2015), National Health Service
Economic Evaluation Database (NHS EED, 1994 to March 2015), and Health Technology
Assessment (HTA). Search terms used were: Crohn’s disease, ulcerative colitis, inflammatory
bowel disease, cost effectiveness, cost utility, cost benefit, health economic, economic evaluation
(see S1 Table for detailed search strategy). Searches were limited to articles published in English
and no date limits were applied. Attempts were made to identify full texts for any conference
abstracts, however, where none were available, the abstracts were excluded due to insufficient
information reported. In addition, a manual search of references from identified literature was
performed. All references were downloaded to EndNote X8 and duplicates were removed.
Study selection
Title, abstract and full-text screening was conducted by NP. Studies were included in the review
according to the PICOS (population, intervention, comparator, outcomes and study design) cri-
teria. Full economic evaluations (cost-effectiveness, cost-benefit and cost-utility analyses) were
included in the review if they included adults (aged18), diagnosed with CD or UC, and com-
pared surgical or pharmacological interventions. Models from drug manufacturers reported in
HTA submissions were also included provided sufficient detail was available. Studies were
excluded from the review if they were partial economic evaluations, if they did not specifically
evaluate treatments for IBD or if they were a letter, comment piece or editorial.
Data extraction and interpretation
Data extraction was conducted based on guidance from the Cochrane Handbook [16]. Data
extracted included disease indication, year and setting, intervention and comparator, perspec-
tive, study design, type of decision analysis (e.g. Markov model or decision tree analysis), time
horizon, source and year of costs, currency, discount rate, source of outcomes and benefits,
sensitivity analysis, and study results. To aid comparisons, costs were inflated to 2015 prices in
US Dollars, using the OECD consumer price index (CPI) [17], and then converted to 2015
purchasing power parity (PPP) using OECD rates [18]. Where the year of cost data collection
was not reported the year of publication was used instead.
The overall cost-effectiveness result, normally expressed in terms of an incremental cost-
effectiveness ratio (ICER), represents the additional cost per unit of effectiveness (often the
quality-adjusted life year (QALY)) achieved from adopting one intervention relative to an
alternative. The ICER was recalculated to reflect 2015 PPP costs per unit of effectiveness, using
the following formula:
ICER ¼
PPP Cost of intervention 1   PPP Cost of intervention 2
Effectiveness of intervention 1   Effectiveness of intervention 2
When interpreting the ICER, interventions were said to be dominant (or dominated) if the
costs of intervention 1 were lower (or higher) and its effectiveness better (or worse) than
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intervention 2. When both the costs and effectiveness of intervention 1 were higher (or lower)
a threshold at which the cost of obtaining an additional unit of effectiveness (or savings for the
loss of effectiveness) is acceptable was normally used. In the UK, the National Institute for
Clinical Excellence (NICE) recommends a technology or drug as cost-effective if it has an
ICER between 20’000 GBP to 30’000 GBP per QALY gained (29’069.77–43’604.65 in 2015
PPP), reflecting the opportunity cost incurred of obtaining an additional QALY had the
money been spent elsewhere in the health system [19]. In the USA, a threshold of 100’000
USD to 150’000 USD has been informally accepted by decision-makers and researchers based
on estimated values of an additional statistical life year [20]. These thresholds are still contested
and subject to change [21–23], therefore, in this study, conclusions drawn with respect to cost-
effectiveness reflect the setting of the original study.
Risk of bias
As recommended by available guidelines, bias assessments were performed using the Drum-
mond et al. (2006) checklist [24] for economic evaluations and the checklist from Philips et al.
(2004) for model-based economic evaluations [25] [26].
Study synthesis
This systematic review presents a narrative summary discussing studies on CD and UC by
clinical presentation (mild, moderate, severe, disease refractory to conventional treatments,
fistulising CD, and surgically-induced remission) and treatment aims (induction, maintenance
and both induction and maintenance). A descriptive analysis of the studies is presented fol-
lowed by the results of cost-effectiveness for individual studies. Based on recommendations
from guidelines for systematic reviews in economic evaluations, no attempts were made to
quantitatively pool study results [26].
Results
Study selection
The literature search revealed 803 records of which 49 full text articles were retained after
removing duplicates and applying the inclusion and exclusion criteria (See Fig 1). Of the
included studies, 24 focus on CD and 25 on UC.
Descriptive analysis
An increasing number of economic evaluations in IBD have been published over the past 20
years (see Fig 2). The oldest study identified on CD was published in 1997, while, the majority
were published from 2000, following the market approval of infliximab. A large increase in
economic evaluations on UC was seen in 2016; however, the first publication identified was in
2007. This reflects both the increasing number of novel pharmacological agents for IBD as well
as the uptake of economic evaluations in healthcare.
Heterogeneous methods were used to generate cost-effectiveness results across studies
(Table 1). For example, a time horizon of one year or less was used in more than 50% of the
studies on CD but in only 36% of studies on UC. Only 21% and 24% of studies on CD and UC,
respectively, used the recommended lifetime time horizon. Secondly, studies mostly adopted
the health system perspective, particularly the third party payer and the publically funded
health system, reflecting the USA and UK health systems, where the majority of studies were
conducted. Two studies on CD and three studies on UC reported adopting a societal perspec-
tive (i.e. incorporating indirect costs to the patient in the model); however, in three of these
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studies no evidence of indirect costs were found in the publications [28–30]. Studies also dif-
fered in the type of decision analysis used (e.g. static decision analytic models versus Markov
models). Finally, most studies used QALYs as the main effectiveness measure, creating a cost-
utility analysis; while, two studies on CD and two studies on UC undertook a cost-effectiveness
analysis, using outcomes such as number of patients in remission [31, 32], number of surgeries
[32], time spent in remission [33] and the probability of achieving mucosal healing (MH) [34].
Crohn’s disease
The results of the 24 studies on CD are summarised in Table 2.
Moderate or severe CD. Priest et al. (2006) showed that maintenance therapy using aza-
thioprine was dominant compared to methotrexate for patients with moderate to severe CD
due to lower costs of treatment, fewer adverse events, more patients in remission and increased
QALYs [39]. In addition, using first-line infliximab plus azathioprine to induce remission (a
top-down strategy) in newly diagnosed patients with moderate to severe CD was dominant
compared to the standard step-up approach [49].
Compared to standard care, adalimumab induction and maintenance therapy was cost-
effective for severe CD (29’215.03 PPP/QALY) but not for moderate CD (61’323.23 PPP/
QALY) in the UK [42]. Additionally, in a lifetime model, infliximab and adalimumab induc-
tion and maintenance therapy were cost-effective compared to standard care when mainte-
nance therapy was administered for one or two years only [41]. In these studies, induction and
maintenance treatment using adalimumab was cheaper and produced better outcomes com-
pared to infliximab infusions [33, 41, 43].
In a study performed in the USA, for patients who lost response to initial infliximab infu-
sions, switching to adalimumab induction and maintenance therapy was associated with
reduced costs and QALYs compared to increasing the infliximab dose to 10mg/kg; however,
Fig 1. Flow chart of study inclusion based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA)[27].
https://doi.org/10.1371/journal.pone.0185500.g001
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neither strategy was cost-effective (403’359.61 PPP/QALY) [32]. Alternatively, certolizumab
pegol was shown to be a cost-effective third-line biologic agents when compared to natalizu-
mab for induction and maintenance of remission in patients who fail anti-TNF treatment [46].
CD refractory to conventional therapies. For patients with CD refractory to conven-
tional treatments, infliximab induction and maintenance therapy was not cost-effective com-
pared to continued treatment with standard care; ICERs ranged from 122’674.42 PPP/QALY
to 768’704.19 PPP/QALY in European and Canadian healthcare settings [36–38, 47]. Adalimu-
mab induction and maintenance treatment was also not cost-effective at 172’218.88 PPP/
QALY [47]. However, when considering induction doses only, infliximab and adalimumab
were dominant compared to standard care for patients with severe disease and adalimumab
was cost-effective for patients with moderate disease [44]. ICERs for maintenance treatment
strategies, as opposed to induction only and episodic re-treatment (i.e. induce remission, stop
treatment and then re-treat when disease recurs), were very high for both infliximab [36–38,
44] and adalimumab [44].
Comparing biologic agents to each other, infliximab induction and maintenance infusions
were dominant when compared to adalimumab, certolizumab pegol and natalizumab for
patients naive to biologic treatment and refractory to conventional therapies [48] and cost-effec-
tive compared to vedolizumab [53]. For patients who failed to respond to infliximab, adalimu-
mab and standard care induction treatments, evidence suggested switching to vedolizumab may
Fig 2. Frequency of published economic evaluations on Crohn’s disease and ulcerative colitis over time;
grey bars indicate year of market approval by the European Medicines Agency (EMA).
https://doi.org/10.1371/journal.pone.0185500.g002
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be less costly and improve outcomes compared to increasing the dose of adalimumab; however,
at current prices, this was not cost-effective in the USA at 621’851.83 PPP/QALY [51]. Similarly,
in an anti-TNF naive population in the UK, vedolizumab was not cost-effective compared to
standard care, infliximab and adalimumab; however, the gross assumptions made in this model
still need to be validated [53].
Fistulising CD. For patients with fistulising CD, the ICER for infliximab induction and
maintenance infusions compared to standard care was 55’265.19 PPP/QALY in a UK study
[40] and 513’552.06 PPP/QALY in the USA [35], which is above accepted cost-effectiveness
thresholds. Although still not cost-effective, a single infliximab infusion followed by re-treat-
ment if the fistula recurs, was associated with fewer costs per QALY compared to maintenance
infliximab infusions (139’534.88 PPP/QALY versus 170’058.14 PPP/QALY) [37].
Surgical and post-surgical interventions. Only one study evaluated the cost-effective-
ness of surgery [52]. Total colectomy with permanent end ileostomy was found to be cost-
effective compared to total colectomy with ileal pouch-anal anastomosis (IPAA), despite
increased QALYs from IPAA, in male patients with isolated medically refractory colonic
Table 1. Key characteristics of published economic evaluations in Crohn’s disease and ulcerative
colitis.
Characteristics Crohn’s Disease (N, %) Ulcerative Colitis (N, %)
Time horizon
Lifetime 5 (21%) 6 (24%)
10 years 1 (4%) 5 (20%)
5 years 3 (13%) 4 (16%)
2 years 1 (4%) 1 (4%)
1 year 13 (54%) 6 (24%)
32 weeks 0 1 (4%)
12 weeks 0 1 (4%)
Not stated 0 1 (4%)
Other 1 (4%) 0
Setting
USA 10 (42%) 4 (16%)
UK 8 (33%) 11 (44%)
Canada 2 (8%) 2 (8%)
Other 4 (17%) 8 (32%)
Study design
Cost-effectiveness analysis 2 (8%) 2 (8%)
Cost-utility analysis 22 (92%) 23 (92%)
Type of decision analysis
Decision analytic model 8 (33%) 7 (28%)
Markov model 12 (50%) 16 (64%)
Monte Carlo simulation 2 (8%) 0
Markov cohort model 1 (4%) 2 (8%)
Cohort model not clearly defined 1 (4%) 0
Perspective
Third party payer 11 (46%) 6 (24%)
Publically-funded health system 8 (33%) 16 (64%)
Societal 2 (8%) 3 (12%)
Not clear 3 (13%) 0
https://doi.org/10.1371/journal.pone.0185500.t001
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Table 2. Summary of cost-effectiveness results adjusted to 2015 PPP for studies on Crohn’s disease.
Reference (year, country) Clinical presentation Interventions/Comparators* Inflated cost
(2015 PPP)
Outcome (QALY
unless otherwise
stated)
ICER (PPP per
outcome gained)†
Trallori et al. (1997, unclear)
[30]
Patients in remission Maintenance therapy with mesalazine 8’578’448.72 1713.6 8’471.74
No maintenance treatment 8’417’485.58 1694.6 Reference
Arsenau et al. (2001, USA)
[35]
Initial treatment of perianal fistula 6MP /metronidazole combination 4’118.09 0.76 Reference
Initial infliximab induction infusions plus combination with 6MP/
metronidazole if treatment failure
14’234.03 0.78 505’796.84
Initial infliximab induction infusions with episodic reinfusion if treatment
failure
14’389.13 0.78 513’552.06
6MP/metronidazole followed by infliximab induction infusions with
episodic reinfusion if treatment failure
9’482.71 0.77 536’461.97
Marshall et al. (2002,
Canada) [36]
Active disease refractory to
conventional therapies
Strategy A: “usual care” immunosuppressants, intravenous
corticosteroids and surgery
10’278.04 0.6281 Strategy A vs.
Strategy B:
187’890.19
Strategy B: Single infliximab infusion at week 0 13’133.97 0.6433 Strategy C vs.
Strategy B:
487’393.91
Strategy C: Single infliximab infusion at week 0 plus reinfusion for
patients who relapse
14’206.24 0.6455 Strategy D vs.
Strategy C:
719’047.53
Strategy D: Single infliximab infusion at week 0 plus maintenance
infliximab for patients who respond and usual care for patients who do
not respond
22’331.48 0.6568 -
Clark et al. (2003, UK)
Schering-Plough model
[37]‡
Chronic active disease refractory
to conventional therapies
Single infliximab infusion 9’738.37
Episodic infliximab infusions (timing not stated) 15’116.28
Maintenance infliximab infusions (timing not stated) 122’674.42
Placebo Reference
Clark et al. (2003, UK)
Schering-Plough model
[37]‡
Fistulising Crohn’s disease Initial infliximab induction infusions 178’779.07
Initial infliximab induction infusions plus retreatment if fistula reopens 139’534.88
Initial infliximab induction infusions plus maintenance treatment for
patients achieving 100% fistula closure
170’058.14
Placebo Reference
Clark et al. (2003, UK)
Primary economic
evaluation [37]‡
Chronic active disease refractory
to conventional therapies
Infliximab 5mg/kg single infusion 135’529.07
Infliximab 5mg/kg episodic infusions (three re-treatments) 90’139.53
Infliximab (5, 10 and 20mg/kg doses) single infusion 196’704.94
Infliximab (all doses) episodic (three re-treatments) 105’030.52
Placebo Reference
Jaisson-Hot et al. (2004,
France) [38]§
Moderate to severe active
ileocolonic disease refractory to
conventional therapies
Strategy 1a: Initial infliximab infusion plus re-treatment when patients
relapse or do not respond
173’478.98 30.78 60’550.01
Strategy 1b: Initial infliximab infusion plus maintenance infliximab
infusions every 8 weeks
994’937.83 30.78 768’704.19
Strategy 2: Surgery 103’240.97 29.62 Reference
Priest et al. (2006, NZ) [39]
**
Moderate to severe CD indicated
for immuno-suppressive therapy
Azathioprine maintenance therapy 1’220’732.02 877.6 Azathioprine
dominant
Methotrexate maintenance therapy 1’493’388.54 633.4 Reference
Kaplan et al. (2007, USA)
[32]
Moderate to severe disease after
loss of response during
maintenance infliximab treatment
Infliximab dose escalation to 10mg/kg every 8 weeks 33’349.18 0.79 403’359.61
Discontinue infliximab and switch to adalimumab induction and
maintenance therapy
21’248.39 0.76
Lindsay et al. (2008, UK)
[40]
Moderate to severe active luminal
disease
Infliximab initial infusions and maintenance treatment 58’626.42 2.145 48’751.83
Standard care (immunomodulators and/or corticosteroids) 49’558.58 1.959
Lindsay et al. (2008, UK)
[40]
Fistulising Crohn’s Disease Infliximab initial infusions and maintenance therapy 69’773.24 2.449 55’265.19
Standard care (immunomodulators and/or corticosteroids) 58’609.67 2.247
Bodger et al. (2009, UK) [41] Moderate to severe active disease Infliximab infusions for induction of remission followed by maintenance
treatment for 1 year
91’568.88 14.568 34’664.32
Infliximab infusions for induction of remission followed by maintenance
treatment for 2 years
105’941.90 14.901 38’753.63
Adalimumab injection for induction of remission followed by
maintenance treatment for 1 year
85’019.15 14.682 12’462.49
Adalimumab injection for induction of remission followed by
maintenance treatment for 2 year
96’590.34 15.156 18’443.45
Standard care (5ASA, immunosuppressive agents, corticosteroids,
antibiotics, symptomatic therapies, topical therapies and surgery)
79’124.39 14.209 Reference
(Continued)
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Table 2. (Continued)
Reference (year, country) Clinical presentation Interventions/Comparators* Inflated cost
(2015 PPP)
Outcome (QALY
unless otherwise
stated)
ICER (PPP per
outcome gained)†
Loftus et al. (2009, UK) [42] Severe active disease Adalimumab induction and maintenance therapy injection 19’798.38 0.8516 29’215.03
Non-biologic therapy (based on the CLASSIC I trial: placebo and
conventional medications)
16’359.77 0.7339 Reference
Moderate to severe active disease Adalimumab induction and maintenance therapy injection 17’640.61 0.8647 61’323.23
Non-biologic therapy (based on the CLASSIC I trial: placebo and
conventional medications)
12’096.99 0.7743 Reference
Yu et al. (2009, USA) [43] Moderate to severe active disease Adalimumab induction and maintenance injections 40’198.41 0.865 Adalimumab
dominant
Infliximab induction and maintenance infusions 45’902.58 0.851
Bakhshai et al. (2010, USA)
[33]§
Moderate to severe active disease
eligible for second line biologic
therapy
Natalizumab induction and maintenance infusion 74’316.05 4.5 months in
remission
Reference
Infliximab induction and maintenance infusions 67’487.91 2.4 months in
remission
Dominated by
adalimumab
Adalimumab induction and maintenance injection 67’168.35 2.88 months in
remission
4412.16 per month
of remission
Dretzke et al. (2011, UK) [44] Severe active disease refractory to
conventional therapies
Standard care 24’406.85 0.8119 Dominated
Infliximab induction infusions 21’925.23 0.8943 Reference
Infliximab maintenance infusions 34’828.20 0.8957 9’216’407.48
Severe active disease refractory to
conventional therapies
Standard care 24’417.76 0.8118 Dominated
Adalimumab induction infusions 12’832.02 0.8942 Reference
Adalimumab maintenance infusions 25’556.69 0.8956 9’089’051.59
Moderate active disease refractory
to conventional therapies
Standard care 12’035.13 0.8926 Reference
Infliximab induction infusions 17’416.83 0.924 171’391.59
Infliximab maintenance infusions 30’476.26 0.9245 578’091.91
Moderate active disease refractory
to conventional therapies
Standard care 12’035.13 0.8922 Dominated
Adalimumab induction infusions 8’338.17 0.9231 Reference
Adalimumab maintenance infusions 21’208.39 0.9236 25’740’443.62
Ananthakrishnan et al.
(2011, USA) [45]
Patients in surgically-induced
remission after first ileocecal
resection
Antibiotics arm: Metronidazole given post-operatively. No treatment
given if patients experience adverse events on metronidazole unless
disease recurred in which case they received infliximab
3’086.90 0.8209 Reference
Azathioprine arm: Azathioprine given post-operatively. No treatment
given if patients experience adverse events on azathioprine unless
disease recurred in which case they received infliximab induction and
maintenance infusions
3’497.76 0.814 Dominated
No treatment arm: No treatment given post-operatively. Patients who
develop clinical recurrence receive infliximab induction and
maintenance infusions
4’265.14 0.805 Dominated
Tailored infliximab arm: No treatment post-operatively. Patients
receive colonoscopy at 6 months; those at no or mild endoscopic
recurrence risk received no treatment and those at high endoscopic
recurrence risk receive infliximab induction and maintenance infusions
8’728.10 0.8206 Dominated
Upfront infliximab arm: Infliximab standard dose maintenance
infusions given post-operatively. Patients who do not respond to
infliximab receive stop treatment and receive no alternative treatment
but switch to azathioprine if disease recurs. Patients who develop
disease recurrence while on infliximab receive increased infliximab
dose (10mg/kg every 8 weeks).
24’070.22 0.828 2’955’396.77
Ananthakrishnan et al.
(2012, USA) [46]
Moderate to severe disease who
lose response to two prior TNF-
antagonists
Natalizumab induction and maintenance infusion 56’348.98 0.71 600’858.73
Certolizumab pegol induction and maintenance injection 50’340.40 0.7
Blackhouse et al. (2012,
Canada) [47]
Moderate to severe disease
refractory to conventional
therapies
Infliximab induction and maintenance infusions 47’928.87 2.721 197’402.17
Adalimumab induction and maintenance injection 40’304.06 2.701 172’218.88
Usual care: Immunosuppressants and corticosteroids 15’160.10 2.555 Reference
Infliximab strategy vs. Adalimumab strategy 360355.43**
Doherty et al. (2012, USA)
[28]
Patients achieving surgically-
induced remission after intestinal
resection
Infliximab induction and maintenance infusions 27’311.46 0.87 839’477.61
Once daily continuous oral azathioprine 7’273.78 0.86 257’332.31
Once daily continuous oral mesalazine 6’417.28 0.85 Dominated
No treatment 2’127.14 0.84 Reference
Tang et al. (2012, USA) [48] Moderate to severe disease
refractory to conventional
therapies and naive to biologic
agents
Infliximab induction and maintenance infusions 24’658.25 0.796 Dominant
Adalimumab induction and maintenance injection 29’957.07 0.799 Dominated
Certolizumab pegol induction and maintenance injection 31’692.91 0.8 Dominated
Natalizumab induction and maintenance infusion 33’988.52 0.79 Dominated
(Continued)
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CD [52]. To maintain remission post-operatively, maintenance treatment with daily azathi-
oprine was cost-effective compared to infliximab maintenance infusions, mesalazine main-
tenance treatment and no maintenance therapy over a 1 year time horizon [28]. Alternatively,
immediate use of antibiotics was the most cost-effective strategy compared to (a) no post-opera-
tive treatment, (b) treatment with azathioprine, (c) infliximab infusions for patients at risk of
endoscopic recurrence given 6 months after surgery, and (d) immediate post-surgical infliximab
infusions [45].
Table 2. (Continued)
Reference (year, country) Clinical presentation Interventions/Comparators* Inflated cost
(2015 PPP)
Outcome (QALY
unless otherwise
stated)
ICER (PPP per
outcome gained)†
Marchetti et al. (2013, Italy)
[49]§
Moderate to severe newly
diagnosed active disease
Top-down arm: Initial induction infusion with infliximab plus
azathioprine, followed by infliximab re-treatment and continued
azathioprine if symptom exacerbation occurred and finally
methylprednisolone added if necessary
20’174.41 3.9 Top-down strategy
dominant
Step up arm: Induction treatment with methylprednisolone, followed by
re-treatment with methylprednisolone plus azathioprine if relapse
occurred and finally infliximab plus azathioprine added if necessary
21’240.29 3.76
Saito et al. (2013, UK) [50] Moderate to severe disease
refractory to conventional
therapies and naive to biologic
therapy
Infliximab induction and maintenance infusions plus azathioprine 14’717.04 0.668 4’528.59
Infliximab induction and maintenance infusions monotherapy 11’981.77 0.064
Erim et al. (2015, USA) [51] Moderate to severe active disease
that failed to respond to infliximab
and conventional therapies
Adalimumab and vedolizumab without prior dose increase:
Adalimumab induction injections followed by maintenance injections
for responders and switch to vedolizumab maintenance infusion for
non-responders or patients who lose response
42’065.42 0.83 Reference
Adalimumab only without dose increase: Adalimumab induction
injections and maintenance injections for primary responders
44’229.01 0.81 Dominated
Adalimumab and vedolizumab with prior dose increase: Adalimumab
induction injections followed by maintenance injections for primary
responders. For patients who do not respond or lose response receive
adalimumab maintenance dose intensification (weekly) or switch to
vedolizumab induction and maintenance infusion
45’642.71 0.83 621’851.83
Adalimumab only with dose increase: Adalimumab induction injection
followed by adalimumab maintenance therapy every other week for
responders and maintenance therapy weekly for non-responders
48’302.89 0.82 Dominated
Taleban et al. (2016, USA)
[52]
Medically refractory disease with
extensive colitis and no perianal or
small bowel inflammation
Total colectomy with ileal pouch anal anastomosis (IPAA) 172’469.72 10.93 Reference
Total colectomy with permanent end ileostomy (EI) 123’559.09 10.24 70’884.96
Rafia et al. (2016, UK)
Takeda submission [53]
Moderate to severe active disease
after failure of initial therapy
Mixed population:
Vedolizumab induction and maintenance infusion Reference
Conventional therapy (5ASA, immunomodulators, and corticosteroids) 95’213.02
Anti-TNF failed population:
Vedolizumab induction and maintenance infusion Reference
Conventional therapy (5ASA, immunomodulators, and corticosteroids) 149’021.70
Anti-TNF naive population:
Vedolizumab induction and maintenance infusion Reference
Conventional therapy (5ASA, immunomodulators, and corticosteroids) 34’387.06
Infliximab induction and maintenance infusion 40’232.77
Adalimumab induction and maintenance injection 1’147’866.07
* Conventional therapy/standard of care is defined as drug treatment with aminosalicylates, methotrexate, corticosteroids, azathioprine, metronidazole or
surgery; standard dosing approved by FDA and EMA applies unless otherwise specified.
† Unless otherwise stated, the ICER reports the cost per QALY gained
‡ When only ICERs were reported these were converted to 2015 PPP values using the PPP exchange rate for the original currency
§ Year of cost data collection not reported therefore year of publication used to complete PPP conversion
** The indication in this study is “moderate to severe IBD” however, efficacy data was extracted from studies on CD therefore it is assumed that this model
reflects the cost-effectiveness for patients with CD. This lack of clarity is captured in the risk of bias assessment.
https://doi.org/10.1371/journal.pone.0185500.t002
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Ulcerative colitis
The results of the 24 studies on UC are summarised in Table 3.
Mild UC. The cost-effectiveness of high dose MMXTM mesalazine, once daily 2g mesala-
zine and concomitant oral and topical mesalazine compared to standard oral mesalazine for
induction and maintenance of remission was demonstrated across various time horizons in
different health systems; ICERs were dominant in five European studies [57, 58, 62, 63, 66]. In
contrast, in the USA high dose (4.8g/day) maintenance mesalazine was not cost-effective,
despite increased QALYs and decreased risk of flares [56]. Interestingly, an inflammation-tar-
geted re-treatment strategy was shown to dominate maintenance treatment with mesalazine
even when costs of a predictive stool test every 3-months is taken into account [64].
Moderate or severe UC. Only one study evaluated moderate to severe UC eligible for
treatment with conventional medications and found high dose mesalazine was dominant
when administered over a short 12 week time horizon due to lower costs compared to standard
dose mesalazine (5’878.12 PPP/QALY versus 6’105.16 PPP/QALY) [54].
In addition, colectomy soon after diagnosis of severe UC was more cost-effective than first-
line medical therapy (methylprednisolone and azathioprine, followed by infliximab induction
and maintenance therapy); however, this study used single-centre cost values potentially
reducing the generalisability of these results [29].
UC refractory to conventional therapies. Compared to standard care, infliximab induc-
tion and maintenance therapy was either dominated [67, 73, 74] or had very high ICERs [68,
72] in studies reflecting European health systems. On the other hand, infliximab was cost-effec-
tive for patients hospitalised with acute severe exacerbations and refractory to IV steroids com-
pared to continued IV cyclosporine (30’859.85 PPP/QALY) and surgery (18’984.14 PPP/QALY)
[65]. These results support the findings from a similar modelling study based in the UK [61].
Moreover, induction and maintenance treatment with adalimumab produced high ICERs,
ranging from 74,194.48 PPP/QALY in the UK to 317,985.64 PPP/QALY in Canada, compared
to standard care [59, 71, 73]. However, adalimumab was cost-effective in a Canadian setting
when compared to a strategy without adalimumab, including scenarios with no treatment,
treatment with steroids and colectomy [69]. Alternatively, in a lifetime model based in the UK,
surgery dominated anti-TNF agents and conventional therapies in a subgroup of patients
where surgery was acceptable and feasible [73]. When surgery was not feasible, adalimumab
dominated infliximab and golimumab but overall conventional therapies were the most cost-
effective treatment option.
Recent studies in the UK point to the cost-effectiveness of vedolizumab in an anti-TNF alpha
naive population when compared to infliximab, golimumab, adalimumab and conventional
therapies; ICERs for each agent ranged from dominance to 9’787 PPP/QALY [67, 74]. Vedolizu-
mab was associated with the highest QALYs compared to anti-TNF alpha agents over the
patient’s lifetime [74]. Findings from the USA contradicted this, suggesting that vedolizumab
would only be cost-effective as a first-line treatment if drug costs fell below 2’500 USD [34].
Risk of bias assessments
On average, 67% and 71% of criteria were fulfilled from the Drummond et al. (1996) checklist
and 49% and 55% of criteria were fulfilled from the Phillips et al. (2004) checklist for CD and
UC, respectively, representing fair quality (see S3 Table). Studies failed to report details on
the methods of synthesis of effectiveness data, the population from which utility values were
acquired, and disaggregated cost and resource use data. In addition, only 57% of CD studies and
29% of UC studies declared that there were no potential conflicts of interest from researchers
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Table 3. Summary of cost-effectiveness results adjusted to 2015 PPP for studies on ulcerative colitis.
Reference (year,
country)
Clinical presentation Interventions & comparators* Cost (2015
PPP)
Outcome (QALY
unless otherwise
stated)
ICER (PPP per
outcome gained)†
Panes et al. (2007,
Spain) [31]
Active and steroid-dependent moderate to severe
disease
Induction treatment with prednisone followed by 5-ASA maintenance therapy for patients in
remission or azathioprine for non-responders
11’236.97 38.50% achieved
remission
44’320.62 per
remission achieved
Induction treatment with prednisolone followed by 5-ASA maintenance therapy for patients in
remission or granulocyte, monocyte adsorption (GMA)-apheresis for non-responders
21’209.11 61% achieved
remission
Reference
Buckland et al. (2008,
UK) [54]
First line treatment for moderately active disease Induction therapy using high dose mesalazine (4.8g/day) 4’236.30 0.1394 High dose dominant
Induction therapy using standard dose mesalazine (2.4g/day) 4’399.92 0.1378 Reference
Tsai et al. (2008, UK)
[55]
Moderate-severe chronic disease refractory to
conventional therapies responding to initial infliximab
induction infusions
Maintenance infliximab infusions 120’915.32 4.591 49’922.73
Standard care 83’323.50 3.838 Reference
Moderate-severe chronic disease refractory to
conventional therapies in remission after initial infliximab
induction infusions
Maintenance infliximab infusions 98’016.73 4.154 35’799.74
Standard care 84’162.23 3.767 Reference
Yen et al. (2008, USA)
[56]
Mild to moderate disease in remission No maintenance 5ASA: 5-ASA 4.8g/day given during a flare and stopped once remission
achieved
4’145.68 1.75 291’540.46
Maintenance 5ASA: 5-ASA 2.4g/day given for maintenance treatment and escalated to 4.8g/
day after first flare to induce and maintain remission
9’976.49 1.77 Reference
Connolly et al. (2009a,
UK) [57]
Mild to moderate disease in remission Once daily 2g mesalazine maintenance therapy 2’011.20 0.935 Once daily
mesalazine is
dominant
Twice daily 1g mesalazine maintenance therapy 2’396.16 0.931 Reference
Connolly et al. (2009b,
UK) [58]
Mild to moderate active disease Induction treatment with 1g/100ml topical mesalazine plus 4g oral mesalazine combination 4’316.14 0.56 Combination
therapy dominant
Induction treatment with 4g oral mesalazine monotherapy 5’692.92 0.55 Reference
Xie et al. (2009, Canada)
[59]
Moderate to severe disease refractory to conventional
therapies
Strategy A: Standard care (5-ASA or immunosuppressants) 21’506.13 2.015 Reference
Strategy B: Infliximab induction infusions followed by infliximab maintenance infusions if
patient responds. If no response or response lost during maintenance therapy, then switch to
adalimumab induction and maintenance injections. If still no response or if response is lost
switch to surgery.
73’337.79 2.178 317’985.64
Strategy C: Infliximab induction infusions followed by infliximab maintenance infusions if
patient responds. If no response, escalate dose to 10mg/kg infliximab maintenance infusions.
If still no response or response is lost switch to adalimumab induction and maintenance
injections
89’746.54 2.149 509’256.80
Brereton et al. (2010,
UK) [60]
Newly diagnosed or relapsing active mild to moderate
disease
5 year model: Induction and maintenance treatment with MMX mesalazine (1200mg tablets
once a day)
9’582.42 3.445 1’248.48
5 year model: Induction and maintenance treatment with Mesalazine (400mg tablets two to
three times a day)
9’568.69 3.434 Reference
Newly diagnosed or relapsing active mild to moderate
disease
Lifetime model: Induction and maintenance treatment with MMX Mesalazine (1200mg tablets
once a day)
37’196.70 14.861 12’897.00
Lifetime model: Induction and maintenance treatment with Mesalazine (400mg tablets two to
three times a day)
36’693.72 14.822 Reference
Punekar et al. (2010,
UK) [61]
Patients hospitalised with acute severe exacerbations
refractory to intravenous (IV) hydrocortisone
IV cyclosporine plus IV hydrocortisone. If patient responds, switch to oral cyclosporine plus
oral prednisolone and azathioprine. For non-responders, switch to surgery
32’970.62 0.7 Reference
Colectomy: 71% of patients receive illeostomy and 29% of patients receive ileal pouch anal
anastomosis (IPAA)
31’051.18 0.58 15’995.29
Standard care: Continue IV hydrocortisone for 7 days. If patient responds, switch to oral
prednisolone and azathioprine. For non-responders, switch to surgery.
33’702.01 0.68 Dominated
Infliximab induction infusions plus IV hydrocortisone. If patient responds, receive two more
infliximab infusions plus prednisolone and azathioprine. For non-responders, switch to
surgery
36’109.03 0.8 31’384.13
Prenzler et al. (2011,
Germany) [62]
Newly diagnosed or relapsing mild to moderate active
disease
MMX mesalazine (2400mg/day) induction and maintenance therapy for patients who
respond. For non-responders, increase dose to 4800mg/day and if still no response add oral
corticosteroids. If still no response or relapse, patient receives immunosuppressants and/or
IV steroids and surgery if medical treatment continues to fail.
6’902.31 3.32 MMX is dominant
Mesalazine (2400mg/day) induction and maintenance therapy for patients who respond. For
non-responders, increase dose to 4800mg/day and if still no response add oral
corticosteroids. If still no response or relapse, patient receives immunosuppressants and/or
IV steroids and surgery if medical treatment continues to fail.
7’774.18 3.309 Reference
Connolly et al. (2012,
Netherlands) [63]
Mild to moderately active disease Induction treatment with 1g topical mesalazine combined with 4g oral mesalazine 2’989.80 0.56 Combination
therapy is dominant
Induction treatment with 4g oral mesalazine and placebo enema monotherapy 3’989.56 0.55 Reference
Mild to moderate disease in remission Maintenance treatment with once daily 2g mesalazine 1’751.61 0.931 Once daily
mesalazine is
dominant
Maintenance treatment with twice daily 1g mesalazine 2’034.74 0.927 Reference
Park et al. (2012, USA)
[29]
Hospitalised patients with severe pancolitis Standard medical therapy: IV methylprednisolone followed by mesalazine maintenance
treatment for responders; if response lost during maintenance therapy switch to azathioprine.
For methylprednisolone non-responders switch to infliximab induction infusions and
maintenance infusions for responders. For infliximab non-responders, switch to tacrolimus. If
all medical therapies fail, switch to colectomy with IPAA.
261’132.75 20.78 1’631’495.11
Early colectomy with IPAA: Subtotal colectomy and laparoscopic IPAA given after initial
hospitalisation followed by medical treatment for patients with acute or chronic pouchitis.
163’243.05 20.72 Reference
Saini et al. (2012, USA)
[64]
Recently diagnosed, mild to moderate 5-ASA responsive
disease in remission
Inflammation-targeted treatment: patients receive predictive stool testing every 3 months and
those with positive test treated with 3-month course of 5-ASA
25’186.38 4.5 Reference
Symptom-targeted treatment: 5-ASA used for symptomatic disease flares 26’931.90 4.5 623’401.80
Continuous maintenance treatment: 5-ASA maintenance therapy for all patients in remission 28’305.12 4.5 Dominated
(Continued)
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Table 3. (Continued)
Reference (year,
country)
Clinical presentation Interventions & comparators* Cost (2015
PPP)
Outcome (QALY
unless otherwise
stated)
ICER (PPP per
outcome gained)†
Chaudhary et al. (2013,
Netherlands) [65]
Patients hospitalised with acute severe exacerbations
refractory to IV steroids
Infliximab induction infusions followed by infliximab plus azathioprine and oral steroids for
responders. Maintenance treatment continued with azathioprine and oral steroids for
responders. Non-responders or patients who lose response switch to surgery.
23’113.73 0.8 Reference
IV cyclosporine followed by oral cyclosporine plus azathioprine and oral steroids for
responders. Maintenance treatment continued with azathioprine and oral steroids for
responders. Non-responders or patients who lose response switch to surgery.
20’027.74 0.7 30’859.85
Surgery with no concomitant medication use 18’937.22 0.58 18’984.14
Connolly et al. (2014,
Netherlands) [66]
Mild to moderate active disease Induction therapy with once daily mesalazine 4’001.12 0.57 Once daily
mesalazine is
dominant
Induction therapy with twice daily mesalazine 4’583.78 0.56 Reference
Essat et al. (2014, UK)
Takeda submission
[67]‡
Moderate to severe disease refractory or inadequately
responding to conventional therapy and anti-TNF alpha
agents
Whole population (patients who received anti-TNF inhibitor and those who did not):
Conventional therapies: Combination of aminosalicylates, immunomodulators and
corticosteroids
49’122.75
Surgery: 40% of patients have illeostomy and 60% have subtotal proctocolectomy Dominated
Vedolizumab: Induction infusions of vedolizumab followed by maintenance infusions for
responders. For non-responders switch to surgery. For patients who discontinue biologic
treatment switch to conventional therapy
Reference
Moderate to severe disease refractory or inadequately
responding to conventional therapy and anti-TNF alpha
agents
Anti-TNF alpha naive patients:
Conventional therapies (combination of aminosalicylates, immunomodulators and
corticosteroids)
7’172.86
Surgery: 40% of patients have illeostomy and 60% have subtotal proctocolectomy Dominated
Infliximab: Induction infusions of infliximab followed by maintenance infusions for responders.
For non-responders switch to surgery. For patients who discontinue biologic treatment switch
to conventional therapy
Dominated
Adalimumab: Induction injections of adalimumab followed by maintenance injections for
responders. For non-responders switch to surgery. For patients who discontinue biologic
treatment switch to conventional therapy
9’787.08
Golimumab: Induction injections of golimumab followed by maintenance injections for
responders. For non-responders switch to surgery. For patients who discontinue biologic
treatment switch to conventional therapy
Dominated
Vedolizumab: Induction infusions of vedolizumab followed by maintenance infusions for
responders. For non-responders switch to surgery. For patients who discontinue biologic
treatment switch to conventional therapy
Reference
Moderate to severe disease refractory or inadequately
responding to conventional therapy and anti-TNF alpha
agents
Patients who failed TNF-alpha inhibitors:
Conventional therapies: Combination of aminosalicylates, immunomodulators and
corticosteroids
95’892.42
Surgery: 40% of patients have illeostomy and 60% have subtotal proctocolectomy Dominated
Vedolizumab: Induction infusions of vedolizumab followed by maintenance infusions for
responders. For non-responders switch to surgery. For patients who discontinue biologic
treatment switch to conventional therapy
Reference
Archer et al. (2016, UK)
MSD Submission [68]
Moderate to severe disease refractory or inadequately
responding to conventional therapy
Infliximab induction infusions followed by maintenance infusions for responders. For non-
responders, switch to relapse management with IV steroids. For patients who fail IV steroids
switch to colectomy.
64’509.13 5.7 57’765.06
Golimumab induction injections followed by maintenance injections for responders. For non-
responders, switch to relapse management with IV steroids. For patients who fail IV steroids
switch to colectomy.
45’608.55 5.54 40’518.32
Adalimumab induction injections followed by maintenance injections for responders. For non-
responders, switch to relapse management with IV steroids. For patients who fail IV steroids
switch to colectomy.
46’651.89 5.49 Dominated
Immediate colectomy 22’918.28 4.98 Reference
Archer et al. (2016, UK)
Abbvie Submission [68]
Moderate to severe disease refractory or inadequately
responding to conventional therapy
Adalimumab induction and maintenance injections for patients who respond. For non-
responders, dose escalation to 40mg every week and switch to conventional therapies if still
no response. For non-responders to conventional treatments, switch to surgery.
112’700.41 5.73 50’730.06
Conventional therapies: Anti-inflammatory drugs or immunosuppressants). For non-
responders, switch to colectomy
75’160.16 4.99 Reference
Beilman et al. (2016,
Canada) [69]
Moderate to severe active corticosteroid-dependent and/
or intolerant to thiopurine treatment
No adalimumab: Patients receive no treatment and remain in chronically unwell state to avoid
colectomy
89’881.15 3.154 59’398.07
Adalimumab therapy: Adalimumab induction injections and maintenance injections for
responders. For non-responders, switch to steroid therapy.
99’147.25 3.321 Reference
Stawowczyk et al.
(2016, Poland) [70]
Moderate to severe disease refractory or not responding
conventional therapies and contraindicated for
cyclosporine
Public payer perspective: Golimumab and standard care combination induction treatment
followed by maintenance treatment for responders. For non-responders, switch to standard
care alone and, if failure persists, switch to colectomy. Maintenance treatment with
golimumab restricted to 1 year.
53’374.23 19.241 222’355.35
Public payer perspective: Standard care alone induction and maintenance treatment
regardless of response. If disease remains active, switch to colectomy.
26’024.52 19.118 Reference
Moderate to severe active disease refractory or not
responding conventional medical therapies and
contraindicated for cyclosporine
Societal perspective: Golimumab and standard care combination induction treatment
followed by maintenance treatment for responders. For non-responders, switch to standard
care alone and colectomy if failure persists. Maintenance treatment with golimumab
restricted to 1 year.
173’211.58 19.241 212’762.53
Societal perspective: Standard care alone, induction and maintenance treatment regardless
of response. If disease remains active, switch to colectomy.
147’041.79 19.118 Reference
(Continued)
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and funding sources. This likely reflects the growing demand for the pharmaceutical industry to
show not only the clinical effectiveness but also the cost-effectiveness of their products [75].
Table 3. (Continued)
Reference (year,
country)
Clinical presentation Interventions & comparators* Cost (2015
PPP)
Outcome (QALY
unless otherwise
stated)
ICER (PPP per
outcome gained)†
Stawowczyk et al.
(2016, Poland) [71]
Moderate to severe active disease refractory to
conventional medical therapies
Public payer perspective: Adalimumab and standard care combination induction treatment
followed by maintenance treatment for responders. For non-responders, switch to standard
care alone and colectomy if failure persists. Maintenance treatment with golimumab
restricted to 1 year.
27’464.00 15.204 101’409.52
Public payer perspective: Standard care alone induction and maintenance treatment
regardless of response. If disease remains active, switch to colectomy.
13’266.67 15.064 Reference
Societal perspective: Adalimumab and standard care combination induction treatment
followed by maintenance treatment for responders. For non-responders, switch to standard
care alone and colectomy if failure persists. Maintenance treatment with golimumab
restricted to 1 year.
125’020.00 15.204 95’190.48
Societal perspective: Standard care alone induction and maintenance treatment regardless
of response. If disease remains active, switch to colectomy.
111’693.33 15.064 Reference
Stawowczyk et al.
(2016, Poland) [72]
Moderate to severe refractory, intolerant or inadequately
responding to conventional medical therapies
Infliximab and standard care combination: Infliximab plus standard care induction infusions
followed by maintenance therapy for responders. For non-responders, switch to adalimumab
induction injections and maintenance injections for responders. For non-responders to
adalimumab, switch to conventional therapy alone or colectomy.
56’425.63 14.296 229’015.09
Standard care alone: Standard care induction and maintenance treatment. If disease
remains active, switch to colectomy.
16’806.02 14.123 Reference
Tappenden et al. (2016,
UK) [73]
Moderate to severe refractory or intolerant to
conventional medical therapies
Patients in whom surgery is an option:
Colectomy 83’011.66 14.71 Reference
Adalimumab induction injections followed by maintenance injections for responders. For non-
responders, switch to conventional therapy.
134’578.97 10.82 Dominated
Infliximab induction infusions followed by maintenance infusions for responders. For non-
responders, switch to conventional therapy.
142’505.70 10.81 Dominated
Golimumab induction injections followed by maintenance injections for responders. For non-
responders, switch to conventional therapy.
132’904.51 10.63 Dominated
Conventional treatment for induction and maintenance phases (includes 5-ASA,
azathioprine, 6-mercaptopurine, prednisolone)
108’610.90 10.47 Dominated
Moderate to severe refractory or intolerant to
conventional medical therapies
Patients in whom surgery is not an option:
Adalimumab induction injections followed by maintenance injections for responders. For non-
responders, switch to conventional therapy.
134’578.97 10.82 74’194.48
Infliximab induction infusions followed by maintenance infusions for responders. For non-
responders, switch to conventional therapy.
142’505.70 10.81 Extendedly
dominated
Golimumab induction injections followed by maintenance injections for responders. For non-
responders, switch to conventional therapy.
132’904.51 10.63 Extendedly
dominated
Conventional treatment for induction and maintenance phases (includes 5-ASA,
azathioprine, 6-mercaptopurine, prednisolone)
108’610.90 10.47 Reference
Yokomizo et al. (2016,
USA) [34]‡
Moderate to severe active disease naive to biologic
agents
Infliximab 5mg/kg induction and maintenance infusions 99290.01 per MH
achieved
Infliximab 10mg/kg induction and maintenance infusions 123801.38 per MH
achieved
Adalimumab induction and maintenance injections 316757.65 per MH
achieved
Vedolizumab induction and maintenance infusions 302331.36 per MH
achieved
Wilson et al. (2017, UK)
[74]
Moderate to severe active disease refractory,
inadequately responding or lost response to conventional
medical therapies and who are anti-TNF naive
Vedolizumab induction infusions followed by maintenance infusions for responders. For non-
responders, patients who lose response, or patients who discontinue due to adverse events,
switch to conventional therapy. If no response to conventional therapy, switch to another
combination of conventional therapies or surgery.
202’422.62 14.077 Reference
Infliximab induction infusions followed by maintenance infusions for responders. For non-
responders, patients who lose response, or patients who discontinue due to adverse events,
switch to conventional therapy. If no response to conventional therapy, switch to another
combination of conventional therapies or surgery.
209’156.89 13.788 Dominated
Adalimumab induction infusions followed by maintenance infusions for responders. For non-
responders, patients who lose response, or patients who discontinue due to adverse events,
switch to conventional therapy. If no response to conventional therapy, switch to another
combination of conventional therapies or surgery.
197’686.20 13.972 65’565.01
Golimumab induction infusions followed by maintenance infusions for responders. For non-
responders, patients who lose response, or patients who discontinue due to adverse events,
switch to conventional therapy. If no response to conventional therapy, switch to another
combination of conventional therapies or surgery.
203’018.58 13.809 Dominated
Conventional therapy/standard of care is defined as drug treatment with aminosalicylates, methotrexate, corticosteroids, azathioprine, metronidazole or
surgery; standard dosing approved by FDA and EMA applies unless otherwise specified.
†Unless otherwise stated, the ICER reports the cost per QALY gained
‡ When only ICERs were reported these were converted to 2015 PPP values using the PPP exchange rate for the original currency
https://doi.org/10.1371/journal.pone.0185500.t003
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Discussion
This review found that, in general, biologic agents help to improve outcomes in terms of
QALYs and remission rates; however, at current prices they did not provide good value for
money in the majority of clinical situations when compared to conventional therapies. In par-
ticular, when administered to maintain remission and when compared to current conven-
tional therapies, biologic agents were not cost-effective in both CD and UC. Moreover, the
cost-effectiveness of biologic agents compared to each other remains inconclusive, reflecting a
major gap in the literature. Importantly, evidence from CD illustrates the potential for biologic
agents to be cost-effective if initiated early (as a top-down strategy) and when the patient’s life-
time clinical management is considered. In addition, in UC, high dose mesalazine for mild dis-
ease and early surgical intervention for severe and refractory disease showed greater cost-
effectiveness compared to standard of care and biologic agents, respectively. These findings,
however, should be reviewed within the context of the methodologies used and the health sys-
tems represented in the studies.
ICERs for induction and maintenance treatment with infliximab and adalimumab com-
pared to conventional therapies were well above acceptable cost-effectiveness thresholds in
CD and UC refractory to conventional therapies [28, 35–38, 45, 47, 53, 59, 67, 68, 73]. In
clinical practice maintenance treatment with biologic agents is preferred to intermittent re-
treatment strategies due to the potential development of anti-drug antibodies [76]. Several
authors extrapolated the costs and effects of maintenance treatment with biologic agents
over a long time horizon, which could explain the high costs incurred over time. In contrast,
both infliximab and adalimumab were cost-effective for patients with moderate to severe
CD when maintenance treatment was limited to one year [40, 41]. Interestingly, when treat-
ment with adalimumab and infliximab was modelled over the patients’ lifetime rather than
one or two years, the ICERs were no longer cost-effective [41]. This suggests an opportunity
for the cost-effectiveness of biologic agents if short maintenance therapy schedules are
defined and adhered to. Alternatively, maintenance therapy with gradual dose intensifica-
tion or concomitant treatment with immunomodulators have been suggested to reduce the
risk of immunogenicity for both CD and UC; however, the clinical- and cost-effectiveness
of these strategies need to be validated [77–79].
The cost-effectiveness of front-line induction therapy using infliximab in newly diag-
nosed CD patients was an important finding [49]. Current treatment guidelines reserve bio-
logic agents as second-line treatment for moderate to severe disease or when conventional
treatments fail [5, 6]. However, early management of CD with infliximab reduced the rate
of relapse and hospitalisation compared to patients who received upfront steroids [49]. It
has been argued that early intervention with biologic agents in patients who are at high risk
of complications may provide long-lasting benefit and help to alter the clinical course of the
disease (Moss, 2015). Stratifying patients based on their risk of complications soon after
diagnosis may be one way to ensure the value for money of biologic agents is captured [80].
Recent economic evaluations have compared a broader scope of interventions, including
newer biologic agents and surgery. For example, in UC refractory to conventional treatments,
one study showed vedolizumab was cost-effective compared to anti-TNF agents [74], while
another study found surgery was cost-effective compared to conventional and anti-TNF agents
[73]. Such evidence was limited in literature on CD, where only one study, submitted by the
manufacturers of vedolizumab, compared adalimumab, infliximab and conventional treat-
ments to vedolizumab [53]. Importantly, this study had a high risk of bias due to the assump-
tions made in the modelling and because the choice of comparators was not comprehensive.
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Models which incrementally compare treatment strategies are useful for decision-making
since they are in line with routine clinical practice where a broad choice of interventions exists.
An important opportunity for the cost-effectiveness of biologic agents is falling drug prices
over time due to the increasing number of biologic agents available on the market and in the
development pipeline. Moreover, as patents for older biologic agents expire, biologically simi-
lar (biosimilar) versions are entering the market, creating an important opportunity for
increasing access and reducing costs. Biosimilars to infliximab have been available for IBD
since 2013, in Europe, and 2016, in the USA and several biosimilars to adalimumab are in the
pipeline [5]. While biosimilars are not identical in molecular structure to their reference prod-
ucts, they have been shown to have similar safety and efficacy profiles [81]. In addition, biosi-
milars show promise in reducing costs, with initial research suggesting they enter the market
at up to 30% lower cost compared to their reference products [82].
Future research is needed to address the gaps identified in the published literature. Firstly,
indirect costs (i.e. non-medical costs incurred by the patient due to their disease such as
absence from work) were not taken into account in the majority of studies. Indirect costs have
been shown to exceed direct costs because IBD is often diagnosed in adolescence and early
adulthood and therefore impacts patients’ during their peak productive years [83]. Secondly,
studies relied on utility scores from a few studies associated with a high degree of uncertainty
[84–86]. When using secondary data sources, there is a risk of introducing bias when specific
disease states used in the economic model do not match those for which the utilities were
derived. Moreover, evidence suggests, utility scores vary across geographies due to cultural dif-
ferences [87]. In several studies the utility scores were found to impact the overall cost-effec-
tiveness results significantly; therefore, these should be accurately captured with large samples
from the countries evaluated. Future economic models could also help to identify optimal
strategies for the use of biologic agents, including the impact of early adoption, risk stratifica-
tion and the impact of switching between different agents over time [80].
This study has several strengths including that a broad inclusion criteria allowed for an
overall understanding of the commonly evaluated treatments in IBD and their cost-effective-
ness across different clinical presentations and health systems. In addition, by inflating and
converting costs to a common currency we were able to make more reliable comparisons of
results between studies. The review methods were documented a priori and approved by all
co-authors in order to limit bias in the selection of studies. This systematic literature review
incorporates evidence from newer biologic agents and the large number of studies on UC pub-
lished in 2016, which the latest review did not capture [88]. In addition, this review differs
from previous literature reviews which focus only on biologic agents [88] or were less system-
atic and focused on specific agents and/or diseases [89, 90]. One limitation of the review meth-
ods is that one reviewer conducted the literature search, study selection, data extraction and
risk of bias assessments, which may have introduced bias into the selection and critical
appraisal of studies.
Economic evaluations in IBD have become increasingly popular over the last decade due to
the growth of therapeutic options from novel and efficacious biologic agents. While the need
for and benefit of systematic reviews in economic evaluations has been contested by some
authors [91], this review shows that it is an effective tool to gain an understanding of drivers of
treatment costs and benefits across countries. The main limitation to systematic reviews of
economic evaluations is the lack of consensus around acceptable cost-effectiveness thresholds.
Previous reviews used different thresholds including 35’000 Euros/QALY (38’290 USD) [88]
and 100’000 USD/QALY [89]. This study found that studies generally concluded that treat-
ments were cost-effective when ICERs were below 50’000 PPP/QALY. Systematic reviews in
health economics could become more effective as a decision-making tool for clinicians and
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policy makers if consensus on methods of synthesis, taking into account variation in costs
across countries and health systems, can be established.
Conclusion
The results of this review have major implications for future research in this field. Biologic
agents were associated with ICERs above 100’000 PPP/QALY in the majority of studies for CD
and UC; however, their use consistently demonstrated improvements in quality of life and
remission rates. In the future, cost-effectiveness of biologic agents may improve as the market
price falls and with the introduction of biosimilars [82]. Future economic models need to
strengthen existing literature by more accurately reflecting real world treatment pathways,
ensuring the chronic and dynamic nature of IBD is captured and accounting for indirect, as
well as direct costs, incurred by the health system and the patients.
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